Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04092673 · ClinicalTrials.gov registry record · Phase 1

Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

A Phase 1 study of Solid Tumor, Adult, sponsored by Effector Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
14
Study locations

NCT04092673 is a Phase 1 study of Solid Tumor, Adult that is actively recruiting participants, run by Effector Therapeutics. The registered enrollment target is 30 participants, below the 190-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (84% lower). The trial reports 14 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04092673, a Phase 1 study of Solid Tumor, Adult, is actively recruiting participants, sponsored by Effector Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
14
Study locations

Study Summary

This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies.

Conditions Studied

Solid Tumor, Adult

Interventions

  • DRUG Trastuzumab
  • DRUG Fulvestrant
  • DRUG Abemaciclib
  • DRUG Sotorasib
  • DRUG eFT226

Study Locations (14)

California

  • University of Southern California - Los Angeles
  • Valkyrie Clinical Trials - Los Angeles
  • Hoag Memorial Hospital Presbyterian - Newport Beach
  • Stanford University - Palo Alto

New York

  • Memorial Sloan Kettering Cancer Center- Commack - Commack
  • Memorial Sloan Kettering Cancer Center- Westchester - Harrison
  • Memorial Sloan Kettering Cancer Center- David H. Koch Center for Cancer Care - New York

Texas

  • MD Anderson Cancer Center - Houston
  • New Experimental Therapeutics of San Antonio - NEXT Oncology - San Antonio

Michigan

  • START Midwest - Grand Rapids

Nevada

  • Comprehensive Cancer Centers of Nevada - Las Vegas

New Jersey

  • Memorial Sloan Kettering Cancer Center- Monmouth - Middletown

Ohio

  • University of Toledo Medical Center - Toledo

Virginia

  • Virginia Cancer Specialists - Fairfax

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2019-10-25
Est. Completion 2025-03-31
Phase Phase 1

Sponsor

Effector Therapeutics

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04092673

The ClinicalTrials.gov registry entry for NCT04092673 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 190-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (84% lower). The listed sponsor is Effector Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 5 interventions - of which Trastuzumab is the first listed.

NCT04092673 reports 14 study locations spanning 8 distinct geographic areas - top geographies include California, New York, Texas.

Frequently Asked Questions

What is clinical trial NCT04092673 about?

NCT04092673 is a clinical study titled "Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies". This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies.

What is the current status of trial NCT04092673?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2019-10-25. Estimated completion is 2025-03-31.

What conditions does trial NCT04092673 study?

This clinical trial studies the following conditions: Solid Tumor, Adult.

What interventions are being tested in trial NCT04092673?

The interventions under investigation include: Trastuzumab (DRUG), Fulvestrant (DRUG), Abemaciclib (DRUG), Sotorasib (DRUG), eFT226 (DRUG).

Who is sponsoring clinical trial NCT04092673?

This trial is sponsored by Effector Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04092673 being conducted?

This trial has 14 study locations across California, Michigan, Nevada, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor, Adult

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor, Adult

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.